CH683485A5 - Solutions de perfusion, de conservation et de reperfusion d'organes. - Google Patents
Solutions de perfusion, de conservation et de reperfusion d'organes. Download PDFInfo
- Publication number
- CH683485A5 CH683485A5 CH3224/91A CH322491A CH683485A5 CH 683485 A5 CH683485 A5 CH 683485A5 CH 3224/91 A CH3224/91 A CH 3224/91A CH 322491 A CH322491 A CH 322491A CH 683485 A5 CH683485 A5 CH 683485A5
- Authority
- CH
- Switzerland
- Prior art keywords
- mmol
- liter
- solution
- reperfusion
- solutions
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 title claims description 20
- 230000010412 perfusion Effects 0.000 title claims description 10
- 239000003978 infusion fluid Substances 0.000 title claims description 8
- 238000004321 preservation Methods 0.000 title claims description 8
- 239000000243 solution Substances 0.000 claims description 83
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 47
- 230000010410 reperfusion Effects 0.000 claims description 36
- 238000001802 infusion Methods 0.000 claims description 25
- 229960003180 glutathione Drugs 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 108010024636 Glutathione Proteins 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 150000003254 radicals Chemical class 0.000 claims description 12
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- 229960004308 acetylcysteine Drugs 0.000 claims description 8
- 229930195712 glutamate Natural products 0.000 claims description 8
- 239000003761 preservation solution Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 150000003573 thiols Chemical group 0.000 claims description 7
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229960000958 deferoxamine Drugs 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 239000002516 radical scavenger Substances 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 229940123457 Free radical scavenger Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 238000004078 waterproofing Methods 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 230000004094 calcium homeostasis Effects 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229940116901 diethyldithiocarbamate Drugs 0.000 claims description 2
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 claims description 2
- 229940099584 lactobionate Drugs 0.000 claims description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 2
- 230000000670 limiting effect Effects 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- GZFOMNDCXQBAAX-BQBZGAKWSA-N (2s)-2-amino-5-[[(2r)-1-[(2-methoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound COC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O GZFOMNDCXQBAAX-BQBZGAKWSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 description 15
- 238000003860 storage Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 8
- 230000002861 ventricular Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- -1 glutathione Chemical class 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 241000153246 Anteros Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001055 Ischemic Contracture Diseases 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 238000010165 Scheffé test Methods 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001101 cardioplegic effect Effects 0.000 description 1
- 239000008148 cardioplegic solution Substances 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000036722 left ventricular developed pressure Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940072417 peroxidase Drugs 0.000 description 1
- 230000036313 post-ischemic recovery Effects 0.000 description 1
- 230000001292 preischemic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9014424A FR2669189B1 (fr) | 1990-11-20 | 1990-11-20 | Solutions de perfusion et de stockage pour transplantations cardiaques. |
FR9109027A FR2679107B1 (fr) | 1991-07-17 | 1991-07-17 | Solutions de perfusion, de conservation et de reperfusion d'organes. |
Publications (1)
Publication Number | Publication Date |
---|---|
CH683485A5 true CH683485A5 (fr) | 1994-03-31 |
Family
ID=26228338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH3224/91A CH683485A5 (fr) | 1990-11-20 | 1991-11-05 | Solutions de perfusion, de conservation et de reperfusion d'organes. |
Country Status (8)
Country | Link |
---|---|
AT (1) | AT399440B (es) |
BE (1) | BE1006834A3 (es) |
CA (1) | CA2055827C (es) |
CH (1) | CH683485A5 (es) |
DE (1) | DE4138040A1 (es) |
ES (1) | ES2050580B1 (es) |
GB (1) | GB2249937B (es) |
IT (1) | IT1251995B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1007500A3 (fr) * | 1992-09-18 | 1995-07-18 | Pasteur Merieux Serums Vacc | Solution de perfusion, de conservation et de reperfusion d'organes. |
WO1994026103A1 (en) * | 1993-05-07 | 1994-11-24 | Chugai Seiyaku Kabushiki Kaisha | Organ preservative |
DE4325547C2 (de) * | 1993-07-29 | 1997-11-27 | Max Planck Gesellschaft | Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen |
JPH07215801A (ja) * | 1994-01-28 | 1995-08-15 | Senju Pharmaceut Co Ltd | 肺保存剤および肺保存方法 |
JPH07330501A (ja) * | 1994-06-14 | 1995-12-19 | Senju Pharmaceut Co Ltd | 肝保存剤および肝保存方法 |
DE4439477C2 (de) * | 1994-11-08 | 1999-10-21 | Asta Medica Ag | Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie |
DE19706111C2 (de) * | 1997-02-17 | 1999-02-18 | Fresenius Medical Care De Gmbh | Lösung zur Aufbewahrung von Organen |
US5990153A (en) * | 1997-05-05 | 1999-11-23 | Wood; John G. | Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury |
US6045990A (en) * | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
DE19834087C1 (de) * | 1998-07-29 | 2000-03-30 | Mirzaie Sedaposhteh Massoud | Wäßrige Konservierungslösung und Verfahren zur Aufbewahrung tierischen Gewebes |
GB0028414D0 (en) | 2000-11-22 | 2001-01-03 | Univ Leeds | Flush preservation solution |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
GR20180100514A (el) * | 2018-11-07 | 2020-06-15 | Πανεπιστημιο Πατρων | Φαρμακευτικοι συνδυασμοι και κιτ για την προληψη ή την θεραπεια του πονου και αλλων επιπλοκων της ορθοπαιδικης ή αγγειακης χειρουργικης και του πολλαπλου τραυματος |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186253A (en) * | 1978-10-10 | 1980-01-29 | The Green Cross Corporation | Perfusate for preserving organ to be transplanted and preserving method |
US4473552A (en) * | 1981-03-16 | 1984-09-25 | Jost Leonora I | Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells |
US4423600A (en) * | 1982-12-10 | 1984-01-03 | Mckenna Joan J | Method for preservation of living organic tissue by freezing |
SE8403912D0 (sv) * | 1984-07-30 | 1984-07-30 | Pharmacia Ab | Lekemedelssats eller -komposition |
DE3581407D1 (de) * | 1985-09-06 | 1991-02-21 | Nestle Sa | Bewahrung lebender gewebe. |
US4879283A (en) * | 1985-10-03 | 1989-11-07 | Wisconsin Alumni Research Foundation | Solution for the preservation of organs |
US4798824A (en) * | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
ES2007994A6 (es) * | 1988-08-16 | 1989-07-01 | Grino Boira Jose Maria | Medio liquido para perfusion y preservacion de organos. |
US4920044A (en) * | 1988-11-08 | 1990-04-24 | The Cleveland Clinic Foundation | Intracellular flush solution for preserving organs |
US4938961A (en) * | 1989-04-28 | 1990-07-03 | Geoffrey Collins | Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia |
-
1991
- 1991-11-05 CH CH3224/91A patent/CH683485A5/fr not_active IP Right Cessation
- 1991-11-11 IT ITMI912991A patent/IT1251995B/it active IP Right Grant
- 1991-11-18 GB GB9124488A patent/GB2249937B/en not_active Expired - Lifetime
- 1991-11-18 AT AT0228791A patent/AT399440B/de not_active IP Right Cessation
- 1991-11-18 ES ES09102549A patent/ES2050580B1/es not_active Expired - Fee Related
- 1991-11-19 DE DE4138040A patent/DE4138040A1/de not_active Withdrawn
- 1991-11-19 CA CA002055827A patent/CA2055827C/en not_active Expired - Lifetime
- 1991-11-19 BE BE9101067A patent/BE1006834A3/fr not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ITMI912991A1 (it) | 1993-05-11 |
ITMI912991A0 (it) | 1991-11-11 |
CA2055827C (en) | 1999-06-15 |
BE1006834A3 (fr) | 1995-01-03 |
GB2249937A (en) | 1992-05-27 |
AT399440B (de) | 1995-05-26 |
GB2249937B (en) | 1994-02-16 |
DE4138040A1 (de) | 1992-05-21 |
ES2050580B1 (es) | 1994-12-16 |
IT1251995B (it) | 1995-05-27 |
CA2055827A1 (en) | 1992-05-21 |
GB9124488D0 (en) | 1992-01-08 |
ES2050580A1 (es) | 1994-05-16 |
ATA228791A (de) | 1994-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5498427A (en) | Solutions for the perfusion, preservation and reperfusion of organs | |
YTREHUS et al. | Influence of oxygen radicals generated by xanthine oxidase in the isolated perfused rat heart | |
BE1006834A3 (fr) | Solution de perfusion, de conservation et de reperfusion d'organes. | |
Southard | Organ preservation | |
Rabl et al. | A multivitamin infusion prevents lipid peroxidation and improves transplantation performance | |
Flaherty et al. | Reperfusion injury | |
US5552267A (en) | Solution for prolonged organ preservation | |
Taylor | Biology of cell survival in the cold: the basis for biopreservation of tissues and organs | |
Hashimoto et al. | Endothelial cell dysfunction after ischemic arrest and reperfusion: a possible mechanism of myocardial injury during reflow | |
US20070243518A1 (en) | Continuous cardiac perfusion preservation with PEG-HB for improved hypothermic storage | |
US7611830B2 (en) | Device to lavage a blood vessel | |
BE1007500A3 (fr) | Solution de perfusion, de conservation et de reperfusion d'organes. | |
Menasche et al. | Improved recovery of heart transplants with a specific kit of preservation solutions | |
JP2008526987A (ja) | 臓器のための灌流及び/又は保存溶液 | |
US5667962A (en) | Pyruvate thiolester for the prevention of reperfusion injury | |
MX2008007382A (es) | Conservacion y/o perfusion de organos. | |
Okboy et al. | The effect of iloprost and NDGA in ischemia reperfusion injury in rat liver | |
FR2679107A1 (fr) | Solutions de perfusion, de conservation et de reperfusion d'organes. | |
Wagner | Donor heart preservation and perfusion | |
Keith | Oxygen free radicals in cardiac transplantation | |
Marshall | Preservation by simple hypothermia | |
FR2669189A1 (fr) | Solutions de perfusion et de stockage pour transplantations cardiaques. | |
Vara et al. | Beneficial effect of S-adenosylmethionine during both cold storage and cryopreservation of isolated hepatocytes | |
Sun et al. | Superoxide dismutase: enhanced small intestinal preservation | |
FR2723818A1 (fr) | Composition de perfusion pour ameliorer la conservation d'organes vivants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUE | Assignment |
Owner name: PASTEUR MERIEUX SERUMS ET VACCINS TRANSFER- IMTIX- |
|
PL | Patent ceased |